Brain Cancer | Topics

Carboplatin Therapy Intensification Results in Improved 5-Year EFS in Pediatric High-Risk Group 3 Medulloblastoma
August 11, 2021

Pediatric patients with high-risk molecular subgroup group 3 medulloblastoma experienced an improvement in 5-year event-free survival after receiving therapy intensification with carboplatin.

DAY101 Granted Rare Pediatric Disease Designation by the FDA for Pediatric Low-Grade Glioma
July 28, 2021

The phase 2 clinical trial is currently recruiting patients with pediatric low-grade glioma to be treated with DAY101 following a rare pediatric disease designation by the FDA.

FDA Grants Fast Track Designation to Berubicin For Treatment of Recurrent Glioblastoma Multiforme
July 05, 2021

Based on its potential to prolong overall survival in patients with glioblastoma multiforme, berubicin was granted fast track designation for the FDA for the treatment of recurrent disease.